Health Care & Life Sciences » Pharmaceuticals | Marinus Pharmaceuticals Inc.

Marinus Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
9.80
5.00
11.00
23.00
126.00
127
Gross Income
9.80
5.00
11.00
23.00
126.00
127
SG&A Expense
5,369.00
11,915.00
24,421.00
28,219.00
18,917.00
37,052
EBIT
5,378.80
11,920.00
-
28,242.00
19,043.00
37,179
Unusual Expense
152.70
1,192.00
-
-
-
-
Non Operating Income/Expense
-
-
7.00
65.00
20.00
1
Interest Expense
90.60
117.00
475.00
464.00
159.00
-
Pretax Income
5,297.70
10,833.00
24,850.00
28,643.00
18,898.00
36,726
Income Tax
27.80
-
-
-
-
-
Consolidated Net Income
5,269.90
10,833.00
24,850.00
28,643.00
18,898.00
36,726
Net Income
5,269.90
10,833.00
24,850.00
28,643.00
18,898.00
36,726
Net Income After Extraordinaries
5,269.90
10,833.00
24,850.00
28,643.00
18,898.00
36,726
Net Income Available to Common
9,073.90
13,378.00
24,850.00
28,643.00
18,898.00
36,726
EPS (Basic)
3.68
2.17
1.67
1.47
0.80
0.90
Basic Shares Outstanding
13,779.20
6,152.70
14,919.80
19,498.10
23,540.70
40,895.40
EPS (Diluted)
0.66
2.17
1.67
1.47
0.80
0.90
Diluted Shares Outstanding
13,779.20
6,152.70
14,919.80
19,498.10
23,540.70
40,895.40
EBITDA
5,369.00
11,915.00
24,421.00
28,219.00
18,917.00
37,052
Non-Operating Interest Income
19.10
12.00
64.00
128.00
324.00
454
Preferred Dividends
3,804.00
2,545.00
-
-
-
-

About Marinus Pharmaceuticals

View Profile
Address
170 North Radnor Chester Road
Radnor Pennsylvania 19087
United States
Employees -
Website http://www.marinuspharma.com
Updated 07/08/2019
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.